Stocks
Pelthos Therapeutics Inc.PTHS
AMEXHealthcareBiotechnology$20.26
Price as of · delayed, not real-time
A clinical-stage biopharmaceutical company developing therapies for central nervous system disorders, including treatments for Parkinson's disease and other neurodegenerative conditions. Its pipeline focuses on small-molecule candidates targeting unmet medical needs, with early-stage trials determining near-term value. Investors track PTHS for its CNS drug development progress and potential partnership or licensing opportunities.
52W Range: $18.19-$37.50
Congressional Interest in Pelthos Therapeutics Inc. (PTHS)
No congressional trades have been disclosed for Pelthos Therapeutics Inc. (PTHS) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
0
Unique Politicians
0
Buys
0
Sells
0
Who in Congress Is Trading PTHS?
No congressional trades found for this stock.